Abstract Number: 2599 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Mycophenolate In Systemic Sclerosis: A Systemic Review
Background/Purpose: Mycophenolate reduces chronic allograft nephropathy and interstitial fibrosis by inhibiting TGF-β, which is an important molecule in the pathogenesis of systemic sclerosis (SSc). The…Abstract Number: 2600 • 2013 ACR/ARHP Annual Meeting
Shear Wave Elastography: A Novel Quantitative Approach For Evaluating Scleroderma Skin
Background/Purpose: Systemic sclerosis (SSc) is a multi-system disease with both visceral and cutaneous fibrosis. Dermal elasticity is reduced and stiffness increased due to excessive dermal…Abstract Number: 2601 • 2013 ACR/ARHP Annual Meeting
Modified Rodnan Ultrasound Skin Score: An Ultrasound Skin Scoring Approach In Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multi-organ disease characterized by thickening, hardening and tightening of the skin. Skin thickening is described by physical exam…Abstract Number: 2603 • 2013 ACR/ARHP Annual Meeting
Are There Differences In Limited Systemic Sclerosis According To Extension Of Skin Involvement?
Background/Purpose: There is consensus in classifying Systemic Sclerosis (SSc) according to extension of skin involvement as limited and diffuse, using the elbows and knees as…Abstract Number: 2579 • 2013 ACR/ARHP Annual Meeting
Recommendations For Screening and Detection Of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTD) and is one of the leading causes of mortality…Abstract Number: 2562 • 2013 ACR/ARHP Annual Meeting
Inhibition Of SOX9 Phosphorylation Abrogates The Increased Expression Of Profibrotic Genes In Systemic Sclerosis Dermal Fibroblasts
Background/Purpose: SOX9, a high mobility group transcription factor is a master regulator of chondrogenesis and plays a crucial role in the regulation of chondrocyte gene…Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…Abstract Number: 825 • 2013 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis
Background/Purpose: Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by various…Abstract Number: 709 • 2013 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.) Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…Abstract Number: 676 • 2013 ACR/ARHP Annual Meeting
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease
Background/Purpose: To investigate whether patients affected with any of the 3 subsets of early systemic sclerosis (SSc) i.e. Raynaud’s Phenomenon (RP) with SSc marker autoantibody…Abstract Number: 683 • 2013 ACR/ARHP Annual Meeting
HRCT Predictors Of Decline In FVC% predicted—Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials
Background/Purpose: Moderate-to-severe HRCT-defined lung involvement (total lung involvement or fibrosis) is a predictor of decline in FVC% predicted and mortality in SLD. Various staging systems…Abstract Number: 686 • 2013 ACR/ARHP Annual Meeting
Blood Flow In The Hands Of a Predefined Homogeneous Systemic Sclerosis Population: The Presence Of Digital Ulcers and The Improvement With Bosentan
Background/Purpose: Digital ulcers (DU) are complications of systemic sclerosis (SSc) and arise as a result of ischaemia due to vasculopathy of the digital arteries (1).…Abstract Number: 652 • 2013 ACR/ARHP Annual Meeting
Pirfenidone and BIBF1120 Suppress Collagen Synthesis In Skin Fibroblast From Patients With Systemic Sclerosis
Background/Purpose: Pirfenidone (5-methyle-1-phenyl-2- [1H]-pyridone) and BIBF1120 (Nintedanib) are currently evaluated in clinical trials as a potential idiopathic pulmonary fibrosis (IPF). Pirfenidone was approved as the…Abstract Number: 2919 • 2013 ACR/ARHP Annual Meeting
The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis
Background/Purpose: In systemic sclerosis (SSc, scleroderma) vasculopathy can result in the end-stage manifestation of a digital ulcer (DU). We hypothesized that bedside flow mediated dilatation…Abstract Number: 2307 • 2012 ACR/ARHP Annual Meeting
Role of Endosomal and Cell Membrane Toll-Like Receptors in Keratinocyte Activation by Systemic Sclerosis Autoantibodies
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune rare connective tissue disorder of unknown aetiology, heterogeneous clinical manifestations and an often progressive course which includes skin…